Clinical Trial Update: Tecfidera and the Gut Microbiota [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on Tecfidera (dimethyl fumarate) and its relationship with the gut microbiota in relapsing multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tecfidera (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: COMPLETED